{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:27:16Z","timestamp":1790774836946,"version":"4.1.0"},"reference-count":32,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Outstanding Youth Fund of the Natural Science Foundation of Xinjiang Uygur Autonomous Region","award":["2022D01E39"],"award-info":[{"award-number":["2022D01E39"]}]},{"name":"Outstanding Doctoral Innovation Project of Xinjiang University","award":["XJU2024BS074"],"award-info":[{"award-number":["XJU2024BS074"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32360185"],"award-info":[{"award-number":["32360185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91742101"],"award-info":[{"award-number":["91742101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianshan Talent Training Program","award":["2023TSYCLJ0043"],"award-info":[{"award-number":["2023TSYCLJ0043"]}]},{"name":"Graduate Research Innovation Project of Xinjiang Uygur Autonomous Region","award":["XJ2025G025"],"award-info":[{"award-number":["XJ2025G025"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As the most powerful professional antigen-presenting cell, dendritic cells (DCs), can effectively activate tumor-specific cytotoxic T lymphocyte responses through antigen cross-presentation (XPT), which involves endosome escape and subsequent degradation by ubiquitin-proteasome system of the exogenous tumor antigen in cytosol. Unfortunately, this important function is often compromised in the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To recover the function of DCs in the antitumor settings, in the present study, we applied PROTAC (proteolysis-targeting chimera) principle in DC vaccine design by chemically linking a small molecular ligand of E3 ubiquitin ligase lenalidomide to a protein antigen ovalbumin (OVA), wrapped in membrane-penetrating nanoparticles calcium carbonate (CaCO\n                      <jats:sub>3<\/jats:sub>\n                      ), which combined both antigen endosome escape and proteasome degradation in DCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The antitumor efficacy of the DC vaccines prepared by the chimeric antigen-containing nanoparticles, lenalidomide-OVA-CaCO\n                      <jats:sub>3<\/jats:sub>\n                      (LOC), termed as LOC-DCs, was found to be much higher than that of normal DC vaccines prepared by OVA wrapped in the same CaCO\n                      <jats:sub>3<\/jats:sub>\n                      particles (OC-DCs), due mechanistically to the accelerated ubiquitination of OVA antigen and its subsequent degradation in the cytosol for major histocompatibility complex I-associated XPT. Interestingly, the antitumor efficacy of the LOC-DC vaccines we made was also proven to be better than that of LOC antigen vaccines in situ, because the LOC-DC vaccines were optimally activated by the chimeric LOC in vitro in terms of C-C motif chemokine receptor 7 (CCR7) and co-stimulatory molecule upregulation for their lymph node migration and T cell stimulation, respectively, in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Together, we established a proof of concept for PROTAC in the DC vaccine design by linking E3 ligase to a protein model antigen, which can be readily replaced with other identified pathogenic antigens to elicit robust cytotoxic immune responses against tumors or viral diseases, and thus has serious implications in the clinics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012405","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:55:14Z","timestamp":1764665714000},"page":"e012405","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["PROTAC-based nanoantigens promote cross-presentation and trafficking of dendritic cell vaccine for enhanced antitumor efficacy"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9100-4706","authenticated-orcid":false,"given":"Peng","family":"Liu","sequence":"first","affiliation":[{"name":"Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhou","sequence":"additional","affiliation":[{"name":"Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Li","sequence":"additional","affiliation":[{"name":"Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Su","sequence":"additional","affiliation":[{"name":"Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuekang","family":"Xu","sequence":"additional","affiliation":[{"name":"Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-6096","authenticated-orcid":false,"given":"Jinyao","family":"Li","sequence":"additional","affiliation":[{"name":"Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2025120200550596000_13.12.e012405.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00707-2"},{"key":"2025120200550596000_13.12.e012405.2","doi-asserted-by":"crossref","first-page":"101848","DOI":"10.1016\/j.smim.2023.101848","article-title":"Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy","volume":"71","author":"Moussion","year":"2024","journal-title":"Semin Immunol"},{"key":"2025120200550596000_13.12.e012405.3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3254"},{"key":"2025120200550596000_13.12.e012405.4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/bs.ircmb.2019.07.005","article-title":"Antigen processing and presentation","volume":"348","author":"Kotsias","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025120200550596000_13.12.e012405.5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tracli.2019.01.006","article-title":"Cross-presentation of Exogenous Antigens","volume":"26","author":"Li","year":"2019","journal-title":"Transfus Clin Biol"},{"key":"2025120200550596000_13.12.e012405.6","doi-asserted-by":"crossref","first-page":"115758","DOI":"10.1016\/j.biopha.2023.115758","article-title":"Antigen cross-presentation in dendric cells: From bench to bedside","volume":"168","author":"Zhang","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025120200550596000_13.12.e012405.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2016.07.019"},{"key":"2025120200550596000_13.12.e012405.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax3769"},{"key":"2025120200550596000_13.12.e012405.9","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.apsb.2024.01.010","article-title":"Expanding the horizons of targeted protein degradation: A non-small molecule perspective","volume":"14","author":"Huang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"2025120200550596000_13.12.e012405.10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.chembiol.2022.08.004","article-title":"Target protein localization and its impact on PROTAC-mediated degradation","volume":"29","author":"Simpson","year":"2022","journal-title":"Cell Chem Biol"},{"key":"2025120200550596000_13.12.e012405.11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature New Biol"},{"key":"2025120200550596000_13.12.e012405.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat Commun"},{"key":"2025120200550596000_13.12.e012405.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851"},{"key":"2025120200550596000_13.12.e012405.14","doi-asserted-by":"publisher","DOI":"10.2174\/1871529x18666180522073855"},{"key":"2025120200550596000_13.12.e012405.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2008.08.003"},{"key":"2025120200550596000_13.12.e012405.16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.177"},{"key":"2025120200550596000_13.12.e012405.17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000252"},{"key":"2025120200550596000_13.12.e012405.18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177788","article-title":"Pharmacological induction of MHC-I expression in tumor cells revitalizes T cell antitumor immunity","volume":"9","author":"Yu","year":"2024","journal-title":"JCI Insight"},{"key":"2025120200550596000_13.12.e012405.19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41551-024-01285-5","article-title":"Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates","volume":"9","author":"Zhao","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"2025120200550596000_13.12.e012405.20","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201704272","article-title":"Exploration of Antigen Induced CaCO 3 Nanoparticles for Therapeutic Vaccine","volume":"14","author":"Wang","year":"2018","journal-title":"Small"},{"key":"2025120200550596000_13.12.e012405.21","doi-asserted-by":"crossref","first-page":"1208349","DOI":"10.3389\/fimmu.2023.1208349","article-title":"Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis enhances antigen cross-presentation and antitumor efficacy through ROS production","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2025120200550596000_13.12.e012405.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101891","article-title":"Immune cell - produced ROS and their impact on tumor growth and metastasis","volume":"42","author":"Kennel","year":"2021","journal-title":"Redox Biol"},{"key":"2025120200550596000_13.12.e012405.23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41435-024-00294-3","article-title":"Next-generation DC vaccines with an immunogenic trajectory against cancer: therapeutic opportunities vs. resistance mechanisms","volume":"26","author":"Sprooten","year":"2024","journal-title":"Genes Immun"},{"key":"2025120200550596000_13.12.e012405.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.141230798"},{"key":"2025120200550596000_13.12.e012405.25","first-page":"505","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025120200550596000_13.12.e012405.26","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.7150\/jca.45678","article-title":"Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting","volume":"11","author":"Wang","year":"2020","journal-title":"J Cancer"},{"key":"2025120200550596000_13.12.e012405.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"},{"key":"2025120200550596000_13.12.e012405.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-2040-6"},{"key":"2025120200550596000_13.12.e012405.29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.9b01326"},{"key":"2025120200550596000_13.12.e012405.30","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025120200550596000_13.12.e012405.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.03.015"},{"key":"2025120200550596000_13.12.e012405.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.2.983"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:55:17Z","timestamp":1764665717000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/jitc-2025-012405"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012405","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}